KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShort-Term Debt repayments
Ratios

Pfizer (PFE) Leases (2019 - 2025)

Pfizer (PFE) has disclosed Leases for 7 consecutive years, with $2.2 billion as the latest value for Q4 2025.

  • On a quarterly basis, Leases fell 3.32% to $2.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.2 billion, a 3.32% decrease, with the full-year FY2025 number at $2.2 billion, down 3.32% from a year prior.
  • Leases was $2.2 billion for Q4 2025 at Pfizer, down from $2.3 billion in the prior quarter.
  • In the past five years, Leases ranged from a high of $3.0 billion in Q4 2022 to a low of $2.2 billion in Q4 2025.
  • A 5-year average of $2.7 billion and a median of $2.8 billion in 2021 define the central range for Leases.
  • Peak YoY movement for Leases: surged 104.83% in 2021, then decreased 21.72% in 2024.
  • Pfizer's Leases stood at $2.8 billion in 2021, then grew by 5.74% to $3.0 billion in 2022, then dropped by 2.6% to $2.9 billion in 2023, then fell by 21.72% to $2.3 billion in 2024, then fell by 3.32% to $2.2 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Leases are $2.2 billion (Q4 2025), $2.3 billion (Q4 2024), and $2.9 billion (Q4 2023).